Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab (Instituto Vital Brasil)
- Development stage
- Preclinical
- Lead developer
- Instituto Vital Brazil
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Trastuzumab (Instituto Vital Brasil) is a biosimilar version of the monoclonal antibody trastuzumab, originally developed by Roche as Herceptin. It is being developed by the Brazilian state-owned laboratory Instituto Vital Brasil in partnership with Bionovis and Merck KGaA as part of Brazil's Partnerships for Productive Development (PDP) program. This initiative facilitates technology transfer to enable the domestic production of high-cost biologic medicines. The drug is a recombinant IgG1 kappa monoclonal antibody that selectively binds with high affinity to the extracellular domain of the human epidermal growth factor receptor 2 (HER2). By targeting HER2, it inhibits the proliferation of tumor cells that overexpress this receptor, which is a characteristic of certain aggressive forms of breast and gastric cancers. The development program includes indications for both early-stage and metastatic HER2-positive breast cancer as well as gastric cancer.
- Other names
- Trastuzumab biosimilar (Instituto Vital Brasil)Trastuzumab (Bionovis/Instituto Vital Brasil)
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on trastuzumab (Instituto Vital Brasil).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab (Instituto Vital Brasil).